HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated…
Pharmaceuticals, Biotechnology and Life Sciences
– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated…
Bethesda, Maryland , June 18, 2021 (GLOBE NEWSWIRE) — Evergreen Therapeutics, Inc. (“Evergreen,” or the “Company”), a fast-growing clinical stage…
Scheduled to Reconvene on June 30, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 18, 2021 (GLOBE NEWSWIRE) —…
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information…
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children…
Presentation to be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases”…
RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…
RESOLUTIONS of the Extraordinary General Meeting Of Shareholders of JSC “Olainfarm” held on June 18th, 2021 1. Reports of the Management Board,…
HANGZHOU, China and SUZHOU, China and NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) — AnHeart Therapeutics Co., Ltd. (“AnHeart”), a…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 18, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED” or…